Composite hydrogel as well as preparation method and application thereof
By introducing CMCS, TA, and Mn2+ into the hydrogel and loading an AMPK agonist, a pH-responsive composite hydrogel was formed, which solved multiple problems of bone defects in elderly patients and achieved a comprehensive improvement in bone repair.
Patent Information
- Application Number
- CN202410936747.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-12
- Publication Date
- 2024-11-08
AI Technical Summary
Existing hydrogels cannot comprehensively address the issues of enhanced osteoblast function, reduced local chronic inflammation, and optimized bone repair microenvironment in elderly patients with bone defects, resulting in limited bone defect healing effects.
Carboxymethyl chitosan (CMCS) was used as the main component, and tannic acid (TA) and Mn2+ were introduced into it to form a composite hydrogel. An AMPK agonist such as metformin was loaded to construct a pH-responsive hydrogel, which enhanced mechanical strength and antibacterial and anti-inflammatory properties and promoted the construction of a bone formation environment.
This composite hydrogel can release drugs in response to specific pH conditions, clear ROS, inhibit bone resorption, promote wound healing, and improve bone repair efficiency, making it suitable for the repair and treatment of bone defects.
Smart Images

Figure CN118903550A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of bioactive materials, and in particular to a composite hydrogel and a preparation method and application thereof. Background Art
[0002] Due to osteoporosis, bone defects in the elderly are mostly osteoporotic. The strength of the bones around the wound is reduced and the healing ability is poor. Most of them are comminuted fractures. The probability of fixation failure or non-union during treatment is high, which is a difficult problem in clinical treatment. The complexity of bone defects in the elderly is multifaceted, rooted in the aging state of the body: (1) Cell aging leads to decreased osteoblast activity; (2) Chronic inflammation caused by various reasons; (3) Aging leads to increased oxidative stress; (4) Due to weakened immune function, the risk of bacterial infection increases.
[0003] The aging process leads to a significant decline in the proliferation and function of osteoblasts, which weakens the natural regeneration process of bones. It is also accompanied by the gradual degeneration of immune function, which reduces the resistance of the elderly to chronic inflammation. The inflammatory response releases a series of harmful inflammatory mediators, which damage the function of osteoblasts, disrupt the normal process of bone remodeling, and hinder the healing of bone defects. Therefore, the proper regulation and management of macrophages is also crucial in the treatment of osteoporotic bone defects in the elderly. Inhibiting the activation of proinflammatory M1 macrophages can reduce chronic inflammation, while enhancing the activity of anti-inflammatory M2 macrophages can help inhibit the inflammatory response and promote tissue repair. In addition, excessive reactive oxygen species (ROS) can induce apoptosis of osteoprogenitor cells and mature osteoblasts, inhibit osteogenic markers such as alkaline phosphatase (ALP), osteocalcin (OCN), and Runt-related transcription factor 2 (RUNX2), thereby destroying the osteogenic differentiation of bone marrow stromal stem cells (BMSC) and MC3T3-E1 cells. Therefore, the removal of ROS is also beneficial to the repair of bone defects.
[0004] Among the traditional bone defect treatment methods, the methods of plate fixation, intramedullary nail implantation, autologous bone transplantation and allogeneic bone transplantation are not suitable for osteoporotic bone defects. In order to treat osteoporotic bone defects, implantable bioactive materials have gradually entered the field of vision of researchers and researchers, which can regulate the local bone balance of the wound, optimize the local microenvironment of bone repair, and provide favorable conditions for bone repair. Among them, hydrogels have shown great potential as drug delivery carriers. For example, the prior art has designed a new PLGA-PEG-PLGA thermosensitive hydrogel, which is composed of polylactic acid-glycolic acid copolymer (PLGA) and polyethylene glycol (PEG), which can prevent and treat early bacterial infections in the osteoporosis FRI model; and a nanocomposite hydrogel scaffold CHAp-PAA, which is composed of nanohydroxyapatite (n-HAp), sodium carbonate (Na2CO3) and polyacrylic acid (PAA), which can effectively promote new bone formation in the pathological environment of osteoporosis. In addition, the prior art has also developed a new type of hyaluronic acid hydrogel for delivering strontium ranelate, which includes calcium carbonate and hyaluronic acid, and helps to restore the balance between osteoclast and osteoblast activity. However, these hydrogels cannot comprehensively solve the problems faced by elderly patients in bone defect repair, such as enhancing osteoblast function, reducing local chronic inflammation, and optimizing the bone repair microenvironment. Therefore, they have limited effects in promoting the effective healing of bone defects. Summary of the invention
[0005] The present invention aims to solve at least one of the above-mentioned technical problems existing in the prior art. To this end, the present invention aims to provide a composite hydrogel using carboxymethyl chitosan (CMCS) as a main component and introducing tannic acid (TA) and Mn 2+ The obtained composite hydrogel can be used to load drugs, which is beneficial to promote wound healing, construct a good bone formation environment, inhibit bone resorption, and improve bone repair efficiency.
[0006] The second aspect of the present invention is to provide a method for preparing the composite hydrogel.
[0007] The third aspect of the present invention is to provide an application of the composite hydrogel.
[0008] In order to achieve the above object, the technical solution adopted by the present invention is:
[0009] The first aspect of the present invention provides a composite hydrogel comprising carboxymethyl chitosan, tannic acid and Mn 2+ ; The mass ratio of the carboxymethyl chitosan to tannic acid is (5-30):1.
[0010] The composite hydrogel obtained by the invention is a pH-responsive hydrogel, which uses carboxymethyl chitosan (CMCS) as a main component and introduces tannic acid (TA) and Mn 2+ Among them, CMCS is a derivative of chitosan, and its excellent biocompatibility and antibacterial properties enable it to be used as a bioactive material. Adding CMCS to the composite hydrogel of the present invention is conducive to constructing a good bone formation environment.
[0011] The specific advantages of carboxymethyl chitosan include the following: 1. Biocompatibility; 2. Promote cell adhesion and proliferation: Osteoblasts need to attach and proliferate to form new bone tissue; 3. Regulate the pH value of the local microenvironment: During bone formation, the pH value of the local microenvironment has an important influence on cell activity and mineral deposition; 4. Promote mineralization: Combine with calcium ions to form a hydroxyapatite structure similar to that in bone tissue, promoting mineral deposition and bone tissue mineralization; 5. Adjustable degradability: It is conducive to obtaining a hydrogel that matches the natural repair rate of bone tissue to support the formation and maturation of new bone tissue; 6. Promote angiogenesis: A good bone formation environment requires angiogenesis to provide the necessary nutrients and oxygen; 7. Antibacterial properties; 8. Injectability and self-healing: It is conducive to implantation and repair of bone injuries; 9. Multifunctionality: It works together with other ingredients or drugs to further promote bone formation.
[0012] Carboxymethyl chitosan (CMC) is a biopolymer derived from chitosan, which has the advantages of good biocompatibility and biodegradability, and is often used in drug delivery systems, tissue engineering, hydrogels and other fields. However, CMC itself has the problem of poor long-term stability in practical applications, especially in aqueous solutions, where it is easily degraded or eroded by microorganisms. The present invention introduces tannic acid (TA) and Mn 2+ , which can form a cross-linked structure, helping to improve the long-term stability of CMC and thus improve the mechanical strength of the composite hydrogel. Tannic acid contains multiple phenolic hydroxyl groups, which can react with Mn 2+ Forming a stable complex, enhancing the cross-linking density of the composite hydrogel, and at the same time, Mn 2+ As a metal ion, it can act as a cross-linker to participate in the formation of metal-ligand cross-links, further improving the stability and mechanical properties of the composite hydrogel.
[0013] In addition, tannic acid (TA), as a polyphenol compound, can improve the performance of hydrogels in many aspects. On the one hand, TA contains a large amount of catechol, which can form strong hydrogen bonds with carboxymethyl chitosan; on the other hand, TA has strong ROS scavenging ability, antibacterial and anti-inflammatory properties, which helps promote wound healing and improve bone repair efficiency.
[0014] Mn is an important component of bones and is involved in protein synthesis for bone tissue regeneration. 2+ , Mn 2+ Mn has the ability to promote osteogenesis and osteogenic differentiation. 2+ It also has the potential to scavenge ROS, which is beneficial to constructing a good bone formation environment and inhibiting bone resorption, forming the bone microenvironment required for bone defects in elderly patients.
[0015] Therefore, the composite hydrogel obtained by the present invention has antibacterial and anti-inflammatory effects, can construct a good bone formation environment and inhibit bone resorption, effectively remove ROS, promote wound healing, improve bone repair efficiency, and can respond to release the loaded drugs under the specific pH environment of the bone defect injury to effectively repair and treat the bone defect.
[0016] In some embodiments of the present invention, the mass ratio of the carboxymethyl chitosan to tannic acid is (8-25):1.
[0017] In some embodiments of the present invention, the mass ratio of the carboxymethyl chitosan to tannic acid is (10-20):1.
[0018] In some embodiments of the present invention, the Mn in the composite hydrogel 2+ The mass content is 13-19%.
[0019] In some embodiments of the present invention, the Mn in the composite hydrogel 2+ The mass content is 14-18%.
[0020] In some embodiments of the present invention, the composite hydrogel is further loaded with an AMPK agonist.
[0021] AMPK (AMP protein kinase) is an important kinase that regulates energy homeostasis. It participates in multiple signal transduction pathways and affects various normal physiological activities of cells, including cell proliferation, autophagy and apoptosis. AMPK agonists can promote osteogenesis, induce osteogenic differentiation and inhibit bone resorption by activating AMP protein kinase (AMPK) and its related pathways.
[0022] In some embodiments of the invention, the AMPK agonist comprises metformin (MET).
[0023] Metformin (MET) is an AMPK agonist. In addition to activating AMPK and regulating osteogenesis and osteoclastogenesis through AMPK, it can also delay aging or alleviate aging-related diseases by targeting key molecules related to aging, has anti-aging effects, and inhibits the adverse effects of aging on bone repair. Therefore, MET can also prevent age-related bone loss, restore autophagic flux, and promote osteogenesis. Combining the anti-aging effect and osteogenic activity of MET, it can simultaneously address the issues of anti-aging, scavenging ROS, antibacterial, inhibiting bone resorption, and promoting osteogenesis.
[0024] In some embodiments of the present invention, the content of the AMPK agonist in the composite hydrogel is 5 to 20 mg / mL.
[0025] In some embodiments of the present invention, the content of the AMPK agonist in the composite hydrogel is 5-15 mg / mL.
[0026] In some specific embodiments of the present invention, the content of AMPK agonist in the composite hydrogel is 8-12 mg / mL.
[0027] The second aspect of the present invention provides a method for preparing the composite hydrogel according to the first aspect of the present invention, comprising the following steps:
[0028] The tannic acid solution and carboxymethyl chitosan are mixed to obtain a CMCS / TA solution, which is allowed to stand to form a CMCS / TA hydrogel;
[0029] The CMCS / TA hydrogel is immersed in a manganese salt solution and allowed to stand to obtain the composite hydrogel.
[0030] It should be noted that the tannic acid solution is a tannic acid aqueous solution.
[0031] In some embodiments of the present invention, the process of mixing the tannic acid solution with carboxymethyl chitosan comprises the following steps:
[0032] Add carboxymethyl chitosan into the tannic acid solution and stir evenly at room temperature.
[0033] In some embodiments of the present invention, the preparation method further comprises the step of loading an AMPK agonist, specifically as follows:
[0034] The CMCS / TA solution is mixed with the acid salt of the AMPK agonist and then allowed to stand to form a CMCS / TA hydrogel loaded with the AMPK agonist.
[0035] In some embodiments of the present invention, the acid salt of the AMPK agonist is a hydrochloride salt.
[0036] In some specific embodiments of the present invention, the acid salt of the AMPK agonist includes metformin hydrochloride.
[0037] In some embodiments of the present invention, the CMCS / TA hydrogel is immersed in the manganese salt solution and then allowed to stand for 100 to 140 minutes.
[0038] In some embodiments of the present invention, the mass concentration of the tannic acid solution is 0.5-2%.
[0039] In some embodiments of the present invention, the mass concentration of the tannic acid solution is 0.5-1.5%.
[0040] In some embodiments of the present invention, the mass concentration of the carboxymethyl chitosan in the tannic acid solution is 10-20%.
[0041] In some embodiments of the present invention, the mass concentration of the carboxymethyl chitosan in the tannic acid solution is 12-17%.
[0042] In some embodiments of the present invention, the mass concentration of the manganese salt solution is 0.2-2%.
[0043] In some embodiments of the present invention, the mass concentration of the manganese salt solution is 0.3-1.5%.
[0044] In some specific embodiments of the present invention, the mass concentration of the manganese salt solution is 0.4-1.2%.
[0045] In some embodiments of the present invention, the manganese salt includes at least one of manganese chloride, manganese nitrate and manganese sulfate.
[0046] In some embodiments of the present invention, the manganese salt acts as a cross-linking agent for forming a composite hydrogel.
[0047] After the CMCS / TA hydrogel is formed, the CMCS / TA hydrogel is immersed in a manganese salt solution, and manganese ions are used as a cross-linking agent to further cross-link the hydrogel, making the hydrogel structure denser and improving the mechanical strength.
[0048] In some embodiments of the present invention, the pH of the tannic acid solution is adjusted to neutral before forming the CMCS / TA hydrogel.
[0049] In some embodiments of the present invention, the pH of the tannic acid solution is adjusted to neutral by NaOH.
[0050] Adjusting the pH to neutral can create suitable conditions for the subsequent cross-linking of manganese ions. Under acidic conditions, the coordination reaction between manganese ions and carboxymethyl chitosan is not easy to occur.
[0051] The third aspect of the present invention provides a use of the composite hydrogel described in the first aspect of the present invention or the composite hydrogel obtained by the preparation method described in the second aspect of the present invention in preparing a bioactive material for treating bone defects.
[0052] In some embodiments of the present invention, the bioactive material is used for combined adjuvant therapy of bone defect internal fixation.
[0053] In some embodiments of the present invention, the bioactive material releases the drug in response to pH, and the pH response range is 5-8.
[0054] The main purpose is to utilize the characteristics of tannic acid to respond to acidic environments. This characteristic may be due to the fact that in an acidic environment, a large number of phenolic hydroxyl groups in tannic acid are more easily protonated to form stable phenolic hydroxyl cations. This protonation strengthens the ionic bonds between tannic acid molecules, which may lead to the relaxation of the hydrogel network and the increase of the pore structure, making it easier for drugs to be released through the hydrogel network. Sensing pH changes in the surrounding environment to achieve controlled release of drugs helps reduce side effects and improve bone repair efficiency.
[0055] Compared with the prior art, the present invention has the following beneficial effects:
[0056] (1) The present invention uses tannic acid and Mn 2+ By improving the network structure and mechanical strength of carboxymethyl chitosan hydrogel, a pH-responsive composite hydrogel with antibacterial and antioxidant properties was obtained. It can construct a good bone formation environment and inhibit bone resorption, effectively remove ROS, promote wound healing, and improve bone repair efficiency. It can also respond to the release of loaded drugs under the specific pH environment of the bone defect injury, and comprehensively solve various problems of bone defects in elderly patients, such as excessive reactive oxygen species (ROS), inflammatory response, and relatively active osteoclasts.
[0057] (2) The composite hydrogel of the present invention can further load the AMPK agonist to activate AMP protein kinase (AMPK) and its related pathways, promote osteogenesis, induce osteogenic differentiation and inhibit bone resorption, and repair and treat bone defects.
[0058] (3) The composite hydrogel of the present invention is suitable for preparing bioactive materials for combined adjuvant treatment of bone defect internal fixation. BRIEF DESCRIPTION OF THE DRAWINGS
[0059] Figure 1 The CMCS / TA hydrogel of Example 4 and Mn 2+ Actual photo of the composite hydrogel formed after cross-linking.
[0060] Figure 2is a scanning electron microscope image of the composite hydrogel of Example 4 and Example 1; wherein, Figure 2 a is the CTM hydrogel of Example 4; Figure 2 b is the MCTM hydrogel of Example 1.
[0061] Figure 3 The Fourier transform infrared spectra (FTIR) of the composite hydrogels of Example 4 and Example 1 and the preparation raw materials are shown.
[0062] Figure 4 This is an energy dispersive X-ray spectrometer (EDS) analysis result diagram of the composite hydrogel of Example 4 and Example 1.
[0063] Figure 5 The results of the CTM hydrogel and CMCS / TA hydrogel of Example 4 and the MCTM hydrogel of Example 1 analyzed by a rotational rheometer are shown in FIG. Figure 5 a is the storage modulus diagram, Figure 5 b is the loss modulus diagram.
[0064] Figure 6 This is a graph showing the release of metformin from the composite hydrogel in Example 1.
[0065] Figure 7 The figure is a graph showing the effect of the extract of the composite hydrogel of Example 4 and Example 1 on the cell viability detection (CCK-8) of bone marrow mesenchymal stem cells (BMSC); wherein, Figure 7 a is the effect after 1 day of cultivation, Figure 7 b is the effect after 3 days of cultivation. Figure 7 c is the effect after 5 days of cultivation.
[0066] Figure 8 The results of real-time fluorescence quantitative reverse transcription PCR (q-RT-PCR) experiments on the hydrogels of Examples 1 to 3 and Comparative Examples 1 to 2 are compared; wherein, Figure 8 a is the relative expression level of RUNX2, Figure 8 b is the relative expression of OPN, Figure 8 c is the relative expression of IL-6, Figure 8 d is the relative expression level of IL-1β.
[0067] Fig. 9 The live cell / dead cell staining (Calcein-AM / PI) staining diagram of the extract of the composite hydrogel of Example 1 and Example 4 on BMSC cells. DETAILED DESCRIPTION
[0068] The present invention is further described in detail below by specific examples. Unless otherwise specified, the raw materials, reagents or devices used in the examples and comparative examples can be obtained from conventional commercial sources or can be obtained by prior art methods. Unless otherwise specified, the experiments or test methods are conventional methods in the art.
[0069] Example 1
[0070] This embodiment provides a composite hydrogel, including carboxymethyl chitosan, tannic acid and Mn 2+ and metformin; the mass ratio of carboxymethyl chitosan to tannic acid is 20:1;
[0071] According to the EDS test results, the Mn 2+ The mass content is 16.07±1.65% (i.e. 14.42%~17.72%);
[0072] The content of metformin in the composite hydrogel is 10 mg / mL.
[0073] The preparation method of the composite hydrogel of this embodiment comprises the following steps:
[0074] A tannic acid (TA) aqueous solution with a mass concentration of 0.75wt% was prepared, and the pH of the solution was adjusted to neutral with NaOH; carboxymethyl chitosan (CMCS) was added to the tannic acid aqueous solution, and stirred evenly at room temperature to make the mass concentration of carboxymethyl chitosan in the tannic acid aqueous solution reach 15wt%, thereby obtaining a CMCS / TA solution; a metformin hydrochloride solution was mixed with the CMCS / TA solution to make the final concentration of metformin hydrochloride 10mg / mL, and the mixture was allowed to stand for 5min to form a MET@CMCS / TA hydrogel; manganese chloride (MnCl) with a mass concentration of 1wt% was used to prepare a tannic acid (TA) aqueous solution. 2 ) solution as a cross-linking agent, and the MET@CMCS / TA hydrogel was immersed in MnCl 2 The solution was allowed to stand for 120 min to form MET@CS / TA / Mn composite hydrogel (MCTM).
[0075] In 5 mL of the MET@CS / TA / Mn composite hydrogel of this example, CMCS is 750 mg, TA is 37.5 mg, and metformin is 50 mg.
[0076] In this example, CMCS / TA hydrogel and Mn 2+ The composite hydrogel formed after cross-linking has a similar appearance to that of Example 1.
[0077] Example 2
[0078] This embodiment provides a composite hydrogel, which is different from Embodiment 1 in that the mass ratio of carboxymethyl chitosan to tannic acid is 10:1.
[0079] The method for preparing the composite hydrogel in this embodiment is different from that in Embodiment 1 in that the mass concentration of the tannic acid aqueous solution is 1.5 wt %.
[0080] Example 3
[0081] This embodiment provides a composite hydrogel, which is different from Embodiment 1 in that the concentration of the manganese chloride solution used in the preparation process is different. The mass concentration of the manganese chloride solution used in this embodiment is 0.4 wt %.
[0082] Example 4
[0083] This embodiment provides a composite hydrogel, including carboxymethyl chitosan, tannic acid and Mn 2+ ; The mass ratio of carboxymethyl chitosan to tannic acid is 20:1.
[0084] The preparation method of the composite hydrogel of this embodiment can refer to the following steps:
[0085] A tannic acid (TA) aqueous solution with a mass concentration of 0.75wt% was prepared, and the pH of the solution was adjusted to neutral with NaOH; carboxymethyl chitosan (CMCS) was added to the tannic acid aqueous solution, and stirred evenly at room temperature to make the concentration of carboxymethyl chitosan in the tannic acid aqueous solution reach 15wt%, thereby obtaining a CMCS / TA solution, which was allowed to stand for 5 minutes to form a CMCS / TA hydrogel; manganese chloride (MnCl) with a mass concentration of 1wt% was used to 2 ) solution as a cross-linking agent, and the CMCS / TA hydrogel was immersed in MnCl 2 The solution was allowed to stand for 120 min to form a CS / TA / Mn composite hydrogel (CTM).
[0086] In this example, CMCS / TA hydrogel and Mn 2+ The composite hydrogel formed after cross-linking is Figure 1 shown.
[0087] Comparative Example 1
[0088] This comparative example provides a hydrogel, which is different from Example 1 in that Mn 2+ Replaced by Ca 2+ ; The difference between the preparation method and Example 1 is that manganese chloride is replaced by calcium chloride.
[0089] Comparative Example 2
[0090] This comparative example provides a hydrogel, which is different from Example 1 in that Mn2+ Replaced by Ca 2+ The difference between the preparation method and Example 1 is that manganese chloride is replaced by zinc chloride.
[0091] Results
[0092] The hydrogels obtained in the above examples and comparative examples were tested, and the results are as follows: Figures 2 to 9 The specific instructions are as follows:
[0093] Figure 2 The SEM images of the composite hydrogels of Example 4 and Example 1 after gelation and freeze drying are shown in the figure. As shown in the figure, it can be seen that after loading metformin, the porosity and pore size distribution of MCTM hydrogels do not change much compared to CTM. This shows that the porous structure of MCTM hydrogel is well maintained during the drug loading process, which is crucial to ensure the continuous and uniform release of drugs.
[0094] Figure 3 The FTIR spectra of the composite hydrogels of Example 4 and Example 1 and the raw materials for preparation are shown in Figure 1. It can be seen that in CMCS, the 3305 cm-1 wavelength, which is usually attributed to the stretching vibration of the hydroxyl group (-OH), -1 The strong broad peak at 3276 cm-1 shifts to 3276 cm-1 after compounding with TA. -1 This spectral change probably indicates that hydrogen bonds are formed between CMCS and TA, which enhances the stability of the composite hydrogel network. -1 The peaks near 1444 cm-1 suggest the formation of metal-oxygen bonds, indicating that the manganese ions are coordinated with the oxygen atoms in CMCS; -1 The band at is attributed to the bending vibration of the N-CH3 group and is one of the characteristic peaks of metformin. This peak appears in the MCTM spectrum and moves to about 1454 cm -1 , confirming the successful integration of metformin. In addition, hydrated manganese chloride (MnCl 2 ) samples also showed characteristic absorption bands corresponding to the vibrational modes of crystalline water molecules in the compound.
[0095] Figure 4 The energy dispersive X-ray spectrometer (EDS) analysis results of the composite hydrogels of Example 4 and Example 1 after gelation and freeze-drying. Through EDS detection and analysis, Mn element was found in the cross section of the composite hydrogel. This result can explain that Mn 2+ The successful combination with CMCS formed a polysaccharide and metal ion complex.
[0096] Figure 5The results of the CTM hydrogel and CMCS / TA hydrogel of Example 4 and the MCTM hydrogel of Example 1 analyzed by a rotational rheometer are shown in FIG. After the two mixtures of CMCS and TA are simply and fully mixed, they are left to stand for 5 to 6 minutes, and colloid formation (CMCS / TA hydrogel) can be observed, which has non-flowability. However, this simple hydrogel has weak mechanical strength and large porosity, and has weak control over drug delivery. By using manganese ions as a cross-linking agent, a CTM composite hydrogel is obtained. Experiments have shown that the use of manganese ions as a cross-linking agent can make the overall network structure of the composite hydrogel dense, which helps to improve the mechanical strength of the composite hydrogel. By analyzing the rheological properties of the hydrogel, it can be seen that after manganese ion cross-linking, the storage modulus and loss modulus of CTM and MCTM hydrogels are significantly improved compared to CMCS / TA hydrogels, and the increase in modulus enables the hydrogel to withstand greater compression and tensile forces, which is beneficial to its maintenance of structural integrity. This change is beneficial for the hydrogel to maintain stability for a longer time at the bone defect site and continue to play a role.
[0097] Figure 6 This is a graph of the release of metformin in the composite hydrogel in Example 1. A standard concentration curve was constructed using metformin solutions with different concentration gradients. The MCTM composite hydrogel in Example 1 was placed in a phosphate buffer solution (PBS), and oscillated at 100 rpm at 37°C to observe the drug release of the MCTM composite hydrogel (10 mg) in 50 mL of PBS with different pH values (5.5 and 7.4). The cumulative release of metformin in the MCTM composite hydrogel was calculated and analyzed using an ultraviolet spectrophotometer, and different absorbances corresponded to different drug concentrations. At the set time points, 2 mL of culture medium was taken out for analysis, and an equal volume of PBS was supplemented after each sampling. The results are shown in Figure 2. Figure 6As shown, the release of metformin showed a biphasic kinetic release trend. In an environment with pH = 7.4, the release of metformin showed a burst release trend within 12 hours, and then the MCTM composite hydrogel showed a sustained release trend for up to 7 days, and finally released about 55% of metformin. In the application scenario of bone defect filling, this is conducive to maintaining local drug concentration, thereby improving the therapeutic effect. When bone defects occur, due to the accumulation of acidic metabolites and cytokines released by inflammatory cells at the site of injury, as well as the production of acidic metabolites caused by possible microbial infection, the wound microenvironment is often weakly acidic. In PBS with pH = 5.5, the metformin release rate of the MCTM composite hydrogel of Example 1 was significantly accelerated, and the cumulative release reached a plateau on about the third day. This feature may be due to the fact that in an acidic environment, a large number of phenolic hydroxyl groups in tannic acid are more easily protonated to form stable phenolic hydroxyl cations. This protonation enhances the ionic bonds between tannic acid molecules, which may lead to the relaxation of the composite hydrogel network and the increase of the pore structure, making it easier for drugs to be released through the hydrogel network. It can be seen that the composite hydrogel of the present invention can sense the pH change of the surrounding environment to achieve controlled release of drugs, which helps to reduce side effects and improve bone repair efficiency.
[0098] The present invention uses a freeze-dried composite hydrogel when conducting the following cell experiment. 3.3 mg of the freeze-dried composite hydrogel is placed in 50 ml of complete culture medium, and an extract is prepared in a shaking incubator at 37° C. and 100 rpm. After 24 hours, the freeze-dried composite hydrogel residue is removed to obtain a complete culture medium containing an MCTM hydrogel component with a metformin concentration of 10 μg / mL, that is, the content of metformin in the composite hydrogel is 10 mg / mL. After the dilution treatment of this process, the final metformin concentration in the culture medium during the experiment is 10 μg / mL.
[0099] Figure 7The effect diagram of the extract of the composite hydrogel of Example 4 (CS / TA / Mn) and Example 1 (Met@CMCS / TA / Mn) of the present invention on the cell viability detection (CCK-8) of bone marrow mesenchymal stem cells (BMSC). In the experiment, BMSC cells were implanted into a 96-well plate at a density of 1000 per well, and these cells were cultured in different culture media for 1 day, 3 days, and 5 days. At these three time points, 10 μL of CCK-8 reagent and 100 μL of fresh complete culture medium corresponding to each group were added to each well; wherein, the culture media were CTM culture medium (containing the composite hydrogel of Example 4), MCTM culture medium (containing the composite hydrogel of Example 1) and conventional complete culture medium (NC group, i.e., Control group / control group). After incubating the cells for 2 hours, at 37°C, the absorbance of the cells was read at a wavelength of 450nm by an enzyme-linked immunosorbent assay (BioTek, USA). The results are as follows Figure 7 As shown, Figure 7 a is the effect after 1 day of cultivation, Figure 7 b is the effect after 3 days of cultivation. Figure 7 c is the effect of culturing for 5 days. It can be seen that the CTM group also has a certain effect of promoting bone formation, which may be due to the effects of TA and Mn 2+ The favorable factors for cells are playing a role; and the osteogenic effect of the MCTM group is better than that of the CTM group (n=5, * and # compared with the Control group and CTM group, respectively, P<0.05).
[0100] Figure 8 The results of real-time fluorescence quantitative reverse transcription PCR (q-RT-PCR) experiments of the hydrogels of Examples 1 to 3 of the present invention and Comparative Examples 1 to 2 are compared. In the expression determination of RUNX2 and OPN, the expression of IL-1β and IL-6 was compared with the positive control group; wherein, the control group used conventional complete culture medium to replace the hydrogel culture medium, and the positive control group used 200ng / mL lipopolysaccharide (LPS) to stimulate RAW264.7 cells for 6h to induce the M1 phenotype, and no hydrogel culture medium was used. A p value of 0.05 is considered statistically significant: *p<0.05, **p<0.01, ***p<0.005, ****p<0.001.
[0101] Among them, Runt-related transcription factor 2 (RUNX2) is a key transcription factor, whose activity and expression level directly affect the generation of osteoblasts, as well as the formation and maintenance of bone tissue. Osteopontin (OPN) is a functionally diverse extracellular matrix protein that plays a key regulatory role in the formation, remodeling and repair of bones. Therefore, the present invention selects Runx2 and OPN genes to evaluate the level of osteogenesis. In the experiment, BMSC cells were cultured for 1 day and 3 days using culture medium containing the hydrogels of Examples 1 to 3 and Comparative Examples 1 to 2, respectively, and then total RNA was isolated, cDNA was synthesized and qRT-PCR was performed; the gene expression level was normalized to the expression level of the endogenous housekeeping gene GAPDH. Figure 8 As shown, among Examples 1 to 3 and Comparative Examples 1 to 2, the expression levels of Runx2 and OPN genes in the Example 1 group were the highest.
[0102] Interleukin-1β (IL-1β) and interleukin-6 (IL-6) are classic inflammatory markers, and as part of the senescence-associated secretory phenotype (SASP), they may affect the inflammatory response and cell behavior of surrounding tissues, thereby participating in the occurrence and development of aging-related diseases. Therefore, the present invention selects IL-1β and IL-6 genes to evaluate the level of cellular inflammation. In the experiment, 200ng / mL lipopolysaccharide (LPS, Sigma) was used to stimulate RAW264.7 cells for 6 hours to induce the M1 phenotype. After rinsing 3 times with PBS, the culture medium was replaced with fresh DMEM culture medium containing 5% FBS, and then the culture medium containing the hydrogels of Examples 1 to 3 and Comparative Examples 1 to 2 was added to culture the cells for 1 day and 3 days, and then total RNA was isolated, cDNA was synthesized and qRT-PCR was performed. The gene expression level was normalized to the expression level of the endogenous housekeeping gene GAPDH. The results are as shown in the figure. Figure 8 It can be seen that the inflammation inhibition ability of the group in Example 1 is the strongest. 2+ As a hydrogel crosslinker, its anti-inflammatory effect is not strong and mainly comes from the biological activity of TA, Ca 2+ Lack of sufficient anti-inflammatory activity, Mn is not effective in clearing chronic inflammation in the bone microenvironment of senile bone defects. 2+ At the same time, the experimental results also prove that the application of Mn 2+ The osteogenic activity and anti-inflammatory activity of Example 1 group were better than those of Zn 2+ 2 groups of comparative examples.
[0103] Fig. 9The live cell / dead cell staining (Calcein-AM / PI) staining diagram of the extract of the composite hydrogel of Example 1 and Example 4 of the present invention on BMSC cells. The live cell / dead cell staining corresponds to the result of CCK-8. During the 5-day culture process, the cell density gradually increased over time, and the groups containing hydrogels (CTM and MCTM) had a certain proliferation effect compared with the control group (CTRL, conventional complete culture medium without hydrogel components), and there were almost no dead cells in the three groups, which proved that the composite hydrogel of the present invention has good biocompatibility.
[0104] In summary, the composite hydrogel of the present invention has antibacterial and anti-inflammatory effects, good biocompatibility, can construct a good bone formation environment and inhibit bone resorption, effectively remove ROS, promote wound healing, improve bone repair efficiency, and can release the loaded drugs (such as metformin) in response to pH to repair and treat bone defects, comprehensively solve various problems of bone defects in elderly patients, and is suitable for preparing bioactive materials for combined adjuvant treatment of bone defect internal fixation.
[0105] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. A composite hydrogel, characterized in that: Including carboxymethyl chitosan, tannic acid and Mn 2+ ; The mass ratio of the carboxymethyl chitosan to tannic acid is (5-30):
1.
2. The composite hydrogel according to claim 1, characterized in that The Mn in the composite hydrogel 2+ The mass content is 13-19%.
3. The composite hydrogel according to claim 1 or 2, characterized in that: The composite hydrogel is also loaded with an AMPK agonist.
4. The composite hydrogel according to claim 3, characterized in that The content of the AMPK agonist in the composite hydrogel is 5 to 20 mg / mL.
5. A method for preparing the composite hydrogel according to any one of claims 1 to 4, characterized in that: The steps include: The tannic acid solution and carboxymethyl chitosan are mixed to obtain a CMCS / TA solution, which is allowed to stand to form a CMCS / TA hydrogel; The CMCS / TA hydrogel is immersed in a manganese salt solution to obtain the composite hydrogel.
6. The preparation method according to claim 5, characterized in that: The step of loading the AMPK agonist is also included, as follows: The CMCS / TA solution is mixed with the acid salt of the AMPK agonist and then allowed to stand to form a CMCS / TA hydrogel loaded with the AMPK agonist.
7. The preparation method according to claim 5, characterized in that: The mass concentration of the tannic acid solution is 0.5-2%; And / or, the mass concentration of the manganese salt solution is 0.2-2%.
8. The preparation method according to any one of claims 5 to 7, characterized in that: Before forming the CMCS / TA hydrogel, the pH of the tannic acid solution was adjusted to neutral.
9. Use of the composite hydrogel according to any one of claims 1 to 4 or the composite hydrogel obtained by the preparation method according to any one of claims 5 to 8 in preparing a bioactive material for treating bone defects.
10. The use according to claim 9, characterized in that: The bioactive material releases drugs in response to pH, and the pH response range is 5-8.
Citation Information
Patent Citations
Autofluorescence bone repairing magnetic sustained-release microspheres
CN103495209A
Artificial bones for recovering bone defects of osteoma and preparation method thereof
CN110237308A
Chitosan healing-promoting gel dressing as well as preparation method and application thereof
CN116212103A
Injectable hydrogels that promote mineralization and afford sustained release of bioactive ions
US20180169141A1
Cited By
Intramedullary nail
CN119632647A
Active composite membrane with asymmetric double-layer structure as well as preparation method and application of active composite membrane
CN121338112A
Metformin nano material as well as preparation method and application thereof
CN121550447A
